World

Moderna vaccine confers at least three months immunity: study

Antibodies remained elevated in study participants, say researchers

Updated 3 years ago · Published on 04 Dec 2020 10:30AM

Moderna vaccine confers at least three months immunity: study
The Moderna vaccine will be reviewed by an advisory committee of the Food and Drug Administration on December 17, and could be greenlit for emergency approval soon after. – Pixabay pic, December 4, 2020

WASHINGTON – The Moderna Covid-19 vaccine, which the company says was recently demonstrated to have 94% efficacy, causes the human immune system to produce potent antibodies that endure for at least three months, a study showed yesterday.

Researchers at the National Institute for Allergies and Infectious Diseases (NIAID), which co-developed the drug, studied the immune response of 34 adult participants, young and old, from the first stage of a clinical trial.

Writing in the New England Journal of Medicine, they said that the antibodies, which stop the SARS-CoV-2 virus from invading human cells, “declined slightly over time, as expected, but they remained elevated in all participants three months after the booster vaccination”.

The vaccine, called mRNA-1273, is administered in two injections given 28 days apart.

Even though the number of antibodies in the study subjects faded over time, it is not necessarily a cause for concern.

NIAID director Anthony Fauci and other experts have said it is very likely that the immune system will remember the virus if reexposed later on, and then produce new antibodies.

Encouragingly, the study showed that the vaccine activated a certain type of immune cell that should help out in the so-called memory response, but only longer term study will confirm if this will really be the case.

“Positives from the study include evidence that a relatively strong antibody response remains 90 days after the second dose of the vaccine,” said virologist Benjamin Neuman, a virologist at Texas A&M University-Texarkana.

“The amount of vaccine-produced antibodies was higher in younger patients than in older patients, but reasonably strong immune responses were still seen even in patients up to 70 years of age.”

The Moderna vaccine will be reviewed by an advisory committee of the Food and Drug Administration on December 17, and could be greenlit for emergency approval soon after.

Like another vaccine produced by Pfizer and BioNTech, it is based on a new technology that uses genetic material in the form of mRNA (messenger ribonucleic acid).

The mRNA is encased in a lipid molecule and injected into the arm, where it causes cells inside our muscles to build a surface protein of the coronavirus.

This tricks the immune system into believing it’s been infected with a microbe, and trains it to build the right kind of antibodies for when it encounters the real virus. – AFP, December 4, 2020

Related News

Culture & Lifestyle / 2w

Family-owned resort beats the odds to ensure no staff was lost during lockdowns

Malaysia / 1mth

Four years ago today - the first lockdown due to Covid-19

Malaysia / 3mth

Four new deaths, 50% surge in Covid-19 variant infections in S’wak

Malaysia / 3mth

No new variants, Covid-19 infection rate under control: Dr Dzul

Malaysia / 4mth

Herd immunity against Covid-19 in place but precautions still needed, warns former Health DG

Malaysia / 4mth

Agong cautions public to prepare for another round of Covid

Spotlight

Business

Penang risks losing high-tech investors to Selangor, says Guan Eng

Malaysia

Selangor Raya open house may be in breach of election laws, Bersih says

Malaysia

MACC confirms probe into Dr Mahathir

Malaysia

Forest City casino: No such thing, says Anwar

EPF introduces flexible account to allow withdrawal

Malaysia

Youth not interested in joining political parties, study shows

By Alfian Z.M. Tahir